A Rutgers neurologist William T. Hu is available to discuss the new drug, Aduhelm, approved by the Food and Drugs Administration to treat Alzheimer’s.
“While there is still a lot of work to be done in understanding this drug, we are entering a new era of treatment for Alzheimer’s disease, which may be beneficial to many patients,” said Hu, an associate professor and chief of cognitive neurology at the Rutgers Robert Wood Johnson Medical School and a researcher at the Rutgers Institute for Health, Health Care Policy, and Aging Research.
“We must note that because the drug specifically targets the brain’s amyloid protein, it should only be given to people with “biomarker-confirmed” Alzheimer’s disease. This means that, in addition to a clinical diagnosis of mild cognitive impairment (MCI) by a physician, additional spinal fluid testing or PET scan is…
